諾泰生物(688076.SH)擬以募集資金向澳賽諾增資並借款以實施募投項目
格隆匯6月4日丨諾泰生物(688076.SH)公佈,公司於2021年6月4日召開第二屆董事會第二十次會議、第二屆監事會第十四次會議,審議通過了《關於使用部分募集資金向全資子公司增資並提供借款用於實施募投項目的議案》,同意公司使用部分募集資金1.5億元用於實施“杭州澳賽諾醫藥中間體建設項目”。其中,公司將以增資的方式向杭州澳賽諾生物科技有限公司(以下簡稱“澳賽諾”)提供7000.00萬元募集資金,以借款的方式向澳賽諾提供8000.00萬元募集資金。
本次增資完成後,澳賽諾的註冊資本將由1.33億元增加至2.03億元,仍為公司全資子公司。此外,以借款的方式向澳賽諾提供的8000.00萬元募集資金,公司將根據項目建設實際資金需求,在借款額度內分期匯入。上述借款期限為1年,借款期限自實際借款之日起算,同時採用同期全國銀行間同業拆借中心公佈的貸款市場報價利率收取利息。借款到期後,經總經理批准可續借,在不影響募投項目建設的情況下,也可提前償還。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.